Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 525 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cholesterol, Elevated Clear all
Completed Phase 2 Interventional Results available

Supplements, Placebo, or Rosuvastatin Study

NCT04846231
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice, Rosuvastatin, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 75 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children

NCT01911390
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Bean powder, Rice bran, Control arm, Bean powder and rice bran
Dietary Supplement
Lead sponsor
Poudre Valley Health System
Other
Eligibility
8 Years to 13 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Fort Collins, Colorado • Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

NCT01588496
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Jul 22, 2026, 12:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation

NCT00388180
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidaemias, Obesity
Interventions
GW501516, GW590735
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 3 Interventional Results available

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT05142722
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
2,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 22, 2026, 12:31 PM EDT
Enrolling by invitation Not applicable Interventional

Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)

NCT05284513
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
FH diagnosis program, Implementation strategy package: Develop and implement tools for quality monitoring, Implementation strategy package: Develop educational materials, Implementation strategy package: Conduct educational outreach visits, Implementation strategy package: Intervene with clinicians and patients to enhance, Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions, Implementation strategy package: Audit and provide feedback, Implementation strategy package: Stage implementation scale up
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
26 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Multiple Locations, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2Phase 3 Interventional

MARS - Monitored Atherosclerosis Regression Study

NCT00116870
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
lovastatin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
21 Years to 67 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 1992
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 3 Interventional Results available

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

NCT02392559
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 17 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
12
States / cities
Farmington, Connecticut • Wilmington, Delaware • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Patient-Spouse Intervention for Self-Managing High Cholesterol

NCT00321789
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
spouse-assisted intervention
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Beef's Unique Food Matrix on Human Health

NCT04841460
View directory record Official record
Conditions
Cholesterol, LDL, Cholesterol, HDL, Research Subjects
Interventions
Low-fat ground beef, High-fat ground beef
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
Male only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2 Interventional

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

NCT02659397
View directory record Official record
Conditions
Hyperlipidemia
Interventions
ETC-1002, Atorvastatin, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Northridge, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

NCT01262118
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 (tasocitinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
9
States / cities
Anniston, Alabama • Little Rock, Arkansas • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Not applicable Interventional Results available

(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol

NCT00526058
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Secura then Futura, Futura then Secura
Device
Lead sponsor
B. Braun Medical Inc.
Industry
Eligibility
25 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Hartford, Connecticut • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

NCT02597127
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Jul 22, 2026, 12:31 PM EDT
Recruiting Phase 2 Interventional

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial

NCT06488105
View directory record Official record
Conditions
Lipid Disorder, Hypercholesterolemia, Cardiovascular Diseases, Atherosclerosis
Interventions
Statin (rosuvastatin 10 or 40 mg daily, depending on risk), Healthy Lifestyle Counseling, Outpatient Followup
Drug · Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 75 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 3 Interventional

A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol

NCT00138762
View directory record Official record
Conditions
Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
96
States / cities
Mobile, Alabama • Mesa, Arizona • Oro Valley, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Short Term Intermittent Fasting and Mediterranean Diet

NCT02148458
View directory record Official record
Conditions
Overweight, Pre-hypertension, Hypertension, Hypercholesterolemia, Glucose Intolerance
Interventions
Mediterranean diet, Control group
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
30 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)

NCT02722408
View directory record Official record
Conditions
Hypercholesteremia
Interventions
Gemcabene
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
17 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Nutritional Supplement Effect on HDL Function

NCT04529174
View directory record Official record
Conditions
HDL
Interventions
CardioLux™HDL, Placebo
Dietary Supplement
Lead sponsor
Metagenics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Comparison of the Effects on Cardiovascular Risk Factors of Korean and American Dietary Profiles

NCT01617525
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Controlled Feeding Dietary Intervention
Other
Lead sponsor
USDA Beltsville Human Nutrition Research Center
Federal
Eligibility
25 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Jul 22, 2026, 12:31 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Children With Diabetes at Risk for Heart Disease.

NCT02275091
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Complications
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
12 Years to 21 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 4 Interventional

Evaluation of Combination Cholesterol Treatments in Patients With High Cholesterol.

NCT00249938
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia
Interventions
Minute Maid Heart Wise orange juice, Welchol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Jul 22, 2026, 12:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia

NCT00690443
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, AEGR-733
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
5
States / cities
Pinellas Park, Florida • Edina, Minnesota • Mogadore, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Jul 22, 2026, 12:31 PM EDT
Not listed Phase 3 Interventional

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

NCT04806893
View directory record Official record
Conditions
Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
Interventions
lerodalcibep, Placebo
Drug · Other
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Jul 22, 2026, 12:31 PM EDT